- Home
- TNXP vs SCNX Comparison
TNXP vs SCNX Comparison
Compare TNXP & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- SCNX
- Stock Information
- Founded
- TNXP 2007
- SCNX 2010
- Country
- TNXP United States
- SCNX United States
- Employees
- TNXP N/A
- SCNX N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- SCNX Other Pharmaceuticals
- Sector
- TNXP Health Care
- SCNX Health Care
- Exchange
- TNXP Nasdaq
- SCNX Nasdaq
- Market Cap
- TNXP 19.5M
- SCNX 59.2M
- IPO Year
- TNXP N/A
- SCNX 2020
- Fundamental
- Price
- TNXP $0.61
- SCNX $7.58
- Analyst Decision
- TNXP Strong Buy
- SCNX
- Analyst Count
- TNXP 2
- SCNX 0
- Target Price
- TNXP $53.50
- SCNX N/A
- AVG Volume (30 Days)
- TNXP 202.5M
- SCNX 12.3K
- Earning Date
- TNXP 11-12-2024
- SCNX 02-10-2025
- Dividend Yield
- TNXP N/A
- SCNX N/A
- EPS Growth
- TNXP N/A
- SCNX N/A
- EPS
- TNXP N/A
- SCNX 3.55
- Revenue
- TNXP $11,291,000.00
- SCNX N/A
- Revenue This Year
- TNXP $62.53
- SCNX $1,085.75
- Revenue Next Year
- TNXP $26.17
- SCNX N/A
- P/E Ratio
- TNXP N/A
- SCNX $3.40
- Revenue Growth
- TNXP 183.05
- SCNX 166.67
- 52 Week Low
- TNXP $0.12
- SCNX $3.69
- 52 Week High
- TNXP $14.08
- SCNX $44.56
- Technical
- Relative Strength Index (RSI)
- TNXP 75.02
- SCNX N/A
- Support Level
- TNXP $0.32
- SCNX N/A
- Resistance Level
- TNXP $0.72
- SCNX N/A
- Average True Range (ATR)
- TNXP 0.15
- SCNX 0.00
- MACD
- TNXP 0.04
- SCNX 0.00
- Stochastic Oscillator
- TNXP 39.61
- SCNX 0.00
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.